SSY Group Gains Approval for New Drug Production in China

SSY Group ( (HK:2005) ) has issued an update.

SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Rosuvastatin Calcium and Ezetimibe Tablets (I), a type 4 chemical drug. This approval marks the third such approval for PRC entities, enhancing the company’s position in the pharmaceutical market by expanding its product offerings for treating hypercholesterolemia and hyperlipidemia, potentially benefiting stakeholders through increased market competitiveness.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is engaged in creating medications for various health conditions, with a market focus on drug consistency and quality evaluation.

YTD Price Performance: -8.54%

Average Trading Volume: 14,144,829

Technical Sentiment Signal: Sell

Current Market Cap: HK$9.33B

Find detailed analytics on 2005 stock on TipRanks’ Stock Analysis page.